AI Article Synopsis
- The study aimed to assess the impact of the GnRH antagonist ganirelix on the endometrium of women with regular menstrual cycles.
- The research involved thirty-five participants across two cycles, evaluating hormonal levels and endometrial changes after treatment with ganirelix compared to a control cycle.
- Results indicated no significant alterations in endometrial thickness or histological dating between the two cycles, although lower serum estradiol and LH levels were observed during the GnRH antagonist treatment.
Article Abstract
Purpose: To study the effects of GnRH antagonist (ganirelix-Orgalutran) on the endometrium of regularly menstruating women.
Materials And Methods: Prospective, self-controlled study. The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm. In both cycles, serum estradiol, LH and endometrial thickness were measured when the largest follicle was > or =18 mm. Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
Results: No statistical differences between histological dating and the endometrial thickness in the control and GnRH antagonist-treated cycles. All morphometric parameters were also not different. Serum estradiol and LH levels were significantly lower in GnRH antagonist-treated cycles.
Conclusion: GnRH antagonist has no effect on the endometrium of regularly menstruating women as assessed by either histological dating or morphometric analysis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455003 | PMC |
| http://dx.doi.org/10.1007/s10815-007-9184-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ovarian sensitivity index affects clinical pregnancy and live birth rates in gonadotropin-releasing hormone agonist and antagonist fertilization cycles.
Front Endocrinol (Lausanne)
December 2024
Taiwan United Birth-Promoting Experts Fertility Clinic, Tainan, Taiwan.
Objectives: This study aimed to investigate the correlation of ovarian sensitivity index (OSI) and clinical parameters in IVF treatments.
Methods: IVF data files between January 2011 and December 2020 in a single unit were included. The primary outcome measure was the correlation between the OSI and clinical pregnancy and live birth rates.
Relugolix reduces leiomyoma extracellular matrix production via the TGF β pathway.
F S Sci
December 2024
Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA; Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD. Electronic address:
Objective: To determine if the oral GnRH antagonist relugolix affects leiomyoma extracellular matrix production through the TGF β pathway DESIGN: Laboratory Study SUBJECTS: None.
Intervention: Exposure of human leiomyoma cells to TGF β and/or relugolix MAIN OUTCOME MEASURES: Production of TGF β, pSMAD2/3, SMAD2/3, COL1A1, FN1 and VCAN in treated and untreated leiomyoma cells RESULTS: TGF β3 production was decreased at 24 hours with relugolix at 10nM (0.80 + 0.
Effects of minipuberty disruption on the expression of sexual behavior in female mice.
Sci Rep
December 2024
Sorbonne Université, CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine - Institut de Biologie Paris Seine, Paris, France.
Sex steroids influence early organization of neural structures involved in expression of sexual behavior. A critical perinatal period during which testosterone surges occur has been identified in male rodents. Data are lacking for females, whose ovarian activity starts later in the postnatal period.
View Article and Find Full Text PDFEffects of gonadotropin-releasing hormone antagonist (GnRH-ant) cessation on trigger day in a GnRH-ant protocol: a meta-analysis.
J Obstet Gynaecol
December 2025
Department of Gynecology, Zunhua People's Hospital, Zunhua, Hebei, China.
Background: The gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is associated with few oocytes retrieved, few mature oocytes and poor endometrial receptivity. Omission of GnRH-ants on trigger day seems unlikely to induce preovulation and may improve outcomes in the GnRH-ant protocol. This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol.
View Article and Find Full Text PDFFlexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial.
Hum Reprod
December 2024
Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an, China.
Study Question: Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment?
Summary Answer: In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy.
What Is Known Already: The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!